Clinical Trial Update: A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting long-term safety of TC-5214 as an adjunct therapy in patients with major depressive disorder; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• TC-5214 (TC-5214)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder, MDD | Phase 3 | Status: COMPLETED | Results posted: 2012-10-29